Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Takeda Gets Option to Acquire US Developer of Gastroparesis Treatment
July 5, 2016
- Takeda Files for Japan Approval of MM Drug Ixazomib
July 5, 2016
- Belsomra Comes Back to Top Position in GP Market: Anterio
July 4, 2016
- Delving into Securities Filings - 1: 1st and 2nd-Tier Makers Continue to Shed Jobs as Generic Peers See Rise in Workforce
July 4, 2016
- Sanofi Japan Completes Merger of Genzyme Japan
July 4, 2016
- Eisai Gives Global R&D Updates on Dementia, Oncology
July 1, 2016
- Filing for 1st Japan-Made Nucleic Acid Expected by Year-End If PIII Yields Positive Data
July 1, 2016
- Toho Holdings Appoints Ex-Qol Exec Takada as Senior Executive Officer
July 1, 2016
- Nichi-Iko Aims for 20% Share of Generic Market in “80% Generic Era”: President
June 30, 2016
- Kyowa Kirin’s KRN23 Gets BT Designation for X-Linked Hypophosphatemia in Children
June 30, 2016
- Novel Anti-HIV Agent Genvoya to Hit Japan Market on July 8: JT, Torii
June 30, 2016
- Celgene Files Revlimid for ATL in Japan
June 30, 2016
- Reconsider Appropriate Diabetes Drug Combos Including GLP-1 Agents: Diabetologist
June 29, 2016
- MSD Initiates Long-Term Observational Study of Treatment with Oral Hypoglycemic Agents
June 29, 2016
- Boehringer-Sanofi Asset Swap Slated to Close by Year’s End; Fate of Japan Units Subject to Future Discussions
June 28, 2016
- Daiichi Sankyo, Servier Sign Sales Accord for Edoxaban in Canada
June 28, 2016
- Takeda Returns Japan Rights for Some Amgen Products
June 27, 2016
- Teijin Pharma Will Block Feburic Generic Erosions by Expanding Indications: President
June 24, 2016
- Cellular Dynamics, US National Eye Institute Ink Pact to Advance Cell Transplantation Therapy for AMD
June 24, 2016
- Univ. of Tokyo, Astellas to Codevelop Rice-Based Oral Cholera Vaccine
June 24, 2016
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…